Takeda Pharmaceutical (TAK) investigational zasocitinib's new drug application for the treatment of adults with moderate-to-severe plaque psoriasis has been accepted for priority review by the US Food and Drug Administration, the company said Monday.
The drug showed "rapid, durable and consistent" skin clearance in a phase 3 trial involving nearly 3,000 patients, the company said.
Shares of the company were up 4.1% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.